Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.1M | $48.6M | $43.0M | $39.9M | — | — | — | — | — | — |
| Revenue growth | — | 34.4% | -11.5% | -7.2% | — | — | — | — | — | — |
| Gross profit | $6.93M | $10.2M | $8.98M | $8.15M | — | — | — | — | — | — |
| Gross margin | 19.2% | 21.1% | 20.9% | 20.4% | — | — | — | — | — | — |
| Operating income | -$5.38M | -$10.9M | -$7.15M | -$2.30M | -$5.62M | -$64.6M | -$27.4M | -$16.4M | -$9.63M | -$8.77M |
| Operating margin | -14.9% | -22.4% | -16.6% | -5.8% | — | — | — | — | — | — |
| Net income | -$2.78M | -$9.07M | -$16.9M | -$2.41M | -$6.86M | -$49.0M | -$18.5M | -$17.3M | -$9.57M | -$8.77M |
| Net margin | -7.7% | -18.7% | -39.3% | -6.0% | — | — | — | — | — | — |
| EPS (diluted) | -$0.21 | -$0.75 | -$20.47 | -$2.83 | -$1.19 | -$2.07 | -$13.00 | -$121.29 | -$228.48 | -$36.24 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.70M | -$2.74M | -$2.57M | -$648K | -$3.89M | -$11.5M | -$17.1M | -$14.1M | -$7.73M | -$8.14M |
| Capital expenditures | — | — | — | — | — | $190K | $584K | $5.18K | — | — |
| Free cash flow | — | — | — | — | — | -$11.6M | -$17.7M | -$14.1M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.38M | $4.88M | $114K | $43.7K | $1.58M | — | — | — | — | — |
| Total assets | $39.5M | $52.2M | $29.6M | $109K | $4.10M | $26.7M | $19.6M | $4.30M | $3.08M | $5.10M |
| Total liabilities | $27.8M | $32.7M | $18.9M | $1.92M | $681K | $4.41M | $4.00M | — | — | — |
| Long-term debt | $1.94M | $1.88M | $6.45K | $740K | — | — | — | — | — | — |
| Shareholders' equity | $11.7M | $19.4M | -$65.5K | -$1.81M | $3.42M | $22.3M | $14.7M | $1.96M | $1.59M | $4.18M |
| Retained earnings | -$3.83M | -$15.0M | -$34.5M | -$4.89M | -$11.8M | -$60.7M | -$79.2M | -$96.5M | -$106M | -$115M |
| Shares (wtd avg diluted) | 13.1M | 15.0M | 952K | 2.13M | 5.75M | 472K | 1.45M | 144K | 41.9B | 335K |
Every figure is extracted from Enveric Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.